ABSTRACT
S
troke accounts for 1 in every 18 deaths in the United States, 1 leaving nearly 30% of patients permanently disabled. 2 Worldwide, stroke is a leading cause of disability and the fourth leading cause of mortality with 6.15 million deaths reported annually. 3 In the United States alone, nearly 800,000 individuals have stroke each year, with a quarter of those being recurrent strokes. 1, 4 Many advances have been made in stroke prevention, imaging, and treatment during the past 20 years. The advent of IV rtPA for AIS in 1995 has improved outcomes for patients presenting within 3 hours, 5 and with ongoing research, the time window for intravenous thrombolysis has been expanded. [6] [7] [8] However, the use of IV rtPA at Ͼ3 hours also carries increased risk of hemorrhagic transformation, 9 which remains a serious complication of ischemic stroke management and occurs in 4%-22% of patients with stroke. 5, 10, 11 HT can be asymptomatic or symptomatic in 3%-25% of cases with resulting worsened outcome. 12 Ongoing effort to find predictors of HT has yielded various factors, including the etiology of stroke, extent of infarction on initial CT, increasing stroke severity (NIHSS score), increasing age, congestive heart failure, high glucose levels, and blood pressure on presentation. 11, [13] [14] [15] [16] [17] Serum markers such as matrix metalloproteinase-9 levels 18 ; imaging modalities such as CT, 19 SPECT, 20 MR imaging, 21 diffusion-and perfusion-weighted MR imaging 22 ; and blood-brain barrier permeability measures on CTP 23 are also under investigation to formulate predictive models for HT.
In this study, we sought to investigate the hypothesis that there are inherent characteristics of ischemic brain tissue measureable by CTP that might predict hemorrhagic transformation. We evaluated the value of CBV, CBF, MTT, and volume of affected brain tissue toward prediction of HT in ischemic stroke.
MATERIALS AND METHODS
This was an institutional review board-approved study conducted at a single academic stroke center receiving Ͼ700 patients with ischemic stroke/TIA annually. The study extended from July 2009 to February 2010, and a cohort of all adult patients presenting with symptoms consistent with stroke/TIA within 12 hours of onset who underwent emergent CTP imaging was selected. At our institution, all patients with stroke presenting within 12 hours of symptom onset undergo CTP imaging. Patients with contraindications to CTP (ie, anaphylactic reaction to contrast, patients with known poor kidney function) were excluded. In addition, patients with a final diagnosis of TIA and those with infratentorial/bilateral/lacunar strokes were excluded. In this study, only patients with a discharge diagnosis of AIS were included in the final cohort.
The medical records were reviewed to obtain age, sex, medical history (hypertension, diabetes, dyslipidemia, coronary artery disease, TIA, stroke), smoking history, medication use, signs and symptoms on arrival, stroke severity at presentation (NIHSS score), use of IV rtPA and endovascular therapy, in-hospital outcome, and functional status on discharge (measured by the mRS). Follow-up noncontrast CT or MR imaging or both were reviewed to document the development of hemorrhagic transformation. "HT" was defined according to the European Cooperative Acute Stroke Study on NCCT as an area of increased attenuation within an area of low attenuation in a typical vascular distribution. 24 On MR imaging, HT was identified by the presence of blood-product signal characteristics on T1, T2, and gradient-echo sequences. "Hemorrhagic transformation" was defined as per the European Cooperative Acute Stroke Study I and II trials and was classified as HI and PH. 15, 24, 25 This was further subdivided into HI 1 and HI 2 and PH 1 and PH 2. "HI 1" was defined as small petechiae along the peripheral margins of infarct. Confluent petechiae within the infarcted region but without mass effect were classified as HI 2. "PH 1" was defined as hematoma with a mass effect of Ͻ30% of the infarcted volume, and a PH with a mass effect of Ͼ30% of infarct volume was classified as PH 2.
The CTP imaging studies of every research patient were analyzed. CTP images were processed by using Vitrea software (Vital Images, Minnetonka, Minnesota) by using a delay-insensitive algorithm (see "Imaging Protocol" below for further details). A freehand region of interest was used to outline the total brain tissue at risk of ischemia as defined by increased MTT and corresponding decreased CBF. A mirrored region of interest was automatically generated by the Vitrea software for measurement of CBF, CBV, and MTT within the contralateral normal brain and was used to normalize CBF, CBV, and MTT values derived for the affected hemisphere. This process is shown in Fig 1. Of note, we considered further subanalyses by breaking down each perfusion parameter measurement into 2 further values (for penumbral and core infarct regions, based on the CBV). 26 However, our sample size limited our ability to make multiple comparisons, and we, therefore, chose to proceed with measurements encompassing the entire ischemic region, as was done by previous authors. 27 A matched case-control cohort was created. Any patient who had HT on follow-up imaging (CT or MR imaging) was considered a "case." Corresponding controls (Յ4) were selected for each of the cases by matching based on IV rtPA administration and presenting NIHSS score (Ϯ2). The matching was performed by using SAS (SAS Institute, Cary, North Carolina) (percentage match, greedy method).
Nonparametric analysis was performed to compare cases and controls by using the Wilcoxon rank sum test. For the initial analysis, all patients with endovascular therapy were excluded. CTP parameters were compared for cases and controls by using the Wilcoxon rank sum test, and P values Ͻ .05 were considered significant. Analysis was then repeated, including endovascular patients as well, but excluding those with SAH or PH that might be interpreted as procedure-related (1 endovascular patient with PH was therefore excluded). Conditional logistic regression was used to analyze the effect of CTP parameters on the development of hemorrhagic transformation, and ROC curves were created. All analyses were performed in SAS 9.2/JMP 9 (SAS Institute).
Imaging Protocol
CTP imaging was performed on a 64-detector CT scanner (Brilliance; Philips Healthcare, Best, the Netherlands) following an initial noncontrast CT scan. This involved successive gantry rotations during IV administration of 50 mL of ioversol (Optiray 350; Mallinckrodt, St. Louis, Missouri) at 5 mL/s followed by a 40-mL saline push. Coverage of 40 mm was obtained, with 8 ϫ 5 mm thick sections, 32 ϫ 1.25 mm collimation, and standard reconstruction. Acquisition parameters were 80 kV(peak), 150 mAs; 2-second cycle time; 30 cycles; 0.4-second rotation; and FOV, 230.
Postprocessing of images was performed by using Vitrea software, Version 3.0.1 (Vital Images). We used whole values derived from each region of interest rather than threshold values, because we have found that data derived from our commercial CTP software is more semiquantitative in nature and we feared that choosing a set uniform threshold across all patients would not account for differences in cardiac output, anatomy, and timing of injections among individual patients. Visually matched areas of increased MTT and decreased CBF were, therefore, outlined as ischemic areas, and all values were then reported as relative to the contralateral hemisphere, to account for potential interpatient variability noted above. The Vitrea software automatically chooses the selected arterial input function and venous output function (typically a proximal A2 vessel and a large dural sinus, respectively). These are verified by the technologist to be anatomically accurate and to result in correct time-to-peak maps of arterial and venous time-intensity curves. In rare cases in which there are discrepancies in the automatic arterial input function and venous output function locations, the arterial input function and venous output function are manually selected by the technologist. We additionally verified each arterial input function and venous output function for all patients included in the study.
RESULTS

Characteristics of the Patient Population
Eighty-three patients with stroke were enrolled in the study. The characteristics of the cohort are presented in Table 1 . Of the total cohort, 16 (19.3%) patients developed HT during their hospital stay. Of these, 37.5% had an early HT (HT within 36 hours of symptom onset). The median duration to the development of HT was 38.7 hours (IQR, 18.8 -52.4 hours).
Characteristics of Matched Cases and Controls
After matching for IV rtPA administration and presenting NIHSS score (Ϯ2), 38 controls were found for 14 cases (no controls were found for 2 patients with HT). There were no differences between cases and controls with respect to age, sex, vital parameters on presentation, history of disease or medication use, initial laboratory investigations, and smoking history ( Table 2) . Cases had a longer hospital stay (median, 8.5 days; IQR, 7-12 days) compared with controls (median, 5 days; IQR, 3-8 days; P ϭ .012). There was a statistically nonsignificant difference between functional outcome assessed at discharge between cases (median mRS score, 5; IQR, 3-5) and controls (median mRS score, 3.5; IQR, 1-5; P ϭ .11). Of the 14 cases, 13 had HI (7 HI 1 and 6 HI 2) and 1 case developed PH 2. Seven cases and 1 control were noted to have undergone endovascular therapy for acute ischemic stroke.
Comparison of Cases and Controls
All cases and controls who had undergone endovascular therapy were excluded (7 cases [accounting for 13 controls] and 1 additional control who received endovascular therapy were excluded). As seen in Table 3 , these remnant cases had higher median total volume at risk of ischemia, longer median rMTT, and lower median rCBF compared with controls, though this did not reach statistical significance. Cases did have a significantly lower median rCBV compared with controls (median rCBV of cases, 0.92; IQR, 0.83-1.07 versus median rCBV of controls, 1.11; IQR, 1.0 -1.29; P ϭ .01). For each 0.1-U decrease in rCBV, the odds of developing an HT increased by 14% (OR, 1.14; 95% CI, 1.05-1.25). The ROC curve for rCBV is shown in Fig 2. The area under the ROC curve was computed to be 0.83 (SE, 0.08; 95% CI, 0.67-0.99), with a cutoff point for rCBV of 1.09. The sensitivity for this cutoff value was 100%, and specificity was 58.3%. Considering that only SAH or PH can truly be interpreted as being procedure-related hemorrhage after endovascular therapy, we repeated the above analysis (excluding cases with both endovascular therapy and SAH/PH [n ϭ 1] and their corresponding controls [n ϭ 2]). Repeat analysis depicted in Table 4 yielded similar results as before: Cases had higher volume at risk of ischemia, longer median rMTT, and lower median rCBF compared with controls. However, this again did not reach statistical significance. The median rCBV was significantly lower in cases compared with controls (median CBVr of cases, 0.92; IQR, 0.78 -1.03 versus median rCBV of controls, 1.09; IQR, 0.97-1.17; P ϭ .004). For each 0.1-U decrease in rCBV, the odds of developing an HT increased by 12% (OR, 1.12; 95% CI, 1.05-1.19). The ROC curve for rCBV is shown in Fig 3. The area under the ROC curve was computed to be 0.78 (SE, 0.08; 95% CI, 0.62-0.94), with a cutoff point for rCBV of 0.98. The sensitivity for a cutoff value of rCBV was 76.92% with a specificity of 72.22%.
DISCUSSION
The incidence of HT has been reported to vary between 2% and 44% of patients with ischemic stroke, 5, 11, 24 and the 19.3% rate observed in our study falls within this range. Besides thrombolytic therapy, HT has been associated with age younger than 65 years, 28 hyperglycemia, 29 acute hypertension 30 and blood pressure variability, 31 low levels of coated platelets, 32 and cardioembolic stroke subtype. 33 As new avenues are explored to stretch the time window for beneficial therapy, 34 there is an increasingly acute need to accurately predict the likelihood of HT in every patient eligible for intervention to judicially triage these patients to available therapies while reducing complications.
Prediction of HT by reduced pretherapeutic CBF, an inherent characteristic of the stroke itself, was first suggested by Ueda et al 35 by using SPECT. A reduction in CBF to Ͻ50% of normal was considered as the critical value for developing HT. 36 Gupta et al 37 in their study of 23 patients with symptomatic stroke or carotid stenosis concluded that mean ipsilateral CBF Ͻ 13 mL/100 g per minute was the cutoff for developing HT. In our cohort, we found that rCBV rather than rCBF was the strongest predictor of HT. This is similar to reports of rCBV (rather than rCBF) being a stronger predictor of penumbra viability in patients with AIS, 26 with similar 38 or even lower 39 values reported by authors for rCBV in patients with HT. In other words, indicators of penumbra viability may also indirectly predict HT, which would be expected to occur more frequently in infarcted core rather than salvageable penumbra regions. We found in our patients that a cutoff rCBV of at least 0.98 could predict development of HT in patients with AIS with 72% specificity.
The role of imaging in acute stroke is ever-expanding.
40,41 Many modalities have shown promise in delineating both the extent of viable brain tissue within the area at ischemic risk as well as in predicting HT. The high risk of HT was associated in the past with an M1 MCA occlusion and lack of collateral flow evaluated by transcranial Doppler, SPECT, and clinical criteria (Toronto Embolic Scale). 20 More recently, BBB permeability studies via MR and CTP imaging have been shown to have a high sensitivity for predicting symptomatic HT. 23, 42 The ROC for rCBV in our study suggests that CBV may also predict HT. The utility of this finding lies in the fact that CT imaging is already a part of the imaging protocol in a large number of tertiary care institutions. CTP as an add-on can be performed easily and quickly in an emergent setting, while providing information about tissue-level hemodynamics, extent of penumbra, and final infarct size. 43 Should our findings be replicated on a larger scale, an additional utility would be prediction of HT, which could further guide emergent treatment decisions for patients with acute stroke.
Limitations
There are several limitations to this study. This was a retrospective study. Effects of stroke severity at presentation and IV rtPA administration were controlled for by matching; however, this reduced the final cohort size. No adjustments were made for specific anatomic locations of perfusion parameters and region-specific risk of HT. Our results represent only a single-institution experience and have not been validated and may, therefore, not be representative of community practice.
CONCLUSIONS
Our data suggest that CTP imaging and, in particular, low rCBV can predict HT in patients with AIS. Should this exploratory analysis be validated in larger studies, initial multimodal CT imaging, including CTP, could be used to triage patients at high risk of HT to treatments less likely to further exacerbate their inherent risk of impending intracerebral hemorrhage. . rCBV represents CBV of the ischemic area normalized to the contralateral side. The cutoff point indicates the threshold at which rCBV can predict HT with optimal sensitivity and specificity.
